Can Vitamin D Supplementation Reduce the Risk of Fracture in the Elderly? A Randomized Controlled Trial ABSTRACT

Size: px
Start display at page:

Download "Can Vitamin D Supplementation Reduce the Risk of Fracture in the Elderly? A Randomized Controlled Trial ABSTRACT"

Transcription

1 JOURNAL OF BONE AND MINERAL RESEARCH Volume 17, Number 4, American Society for Bone and Mineral Research Can Vitamin D Supplementation Reduce the Risk of Fracture in the Elderly? A Randomized Controlled Trial HAAKON E. MEYER, 1,2 GURO B. SMEDSHAUG, 1,2 ELISABETH KVAAVIK, 1,2 JAN A. FALCH, 3 AAGE TVERDAL, 1 and JAN I. PEDERSEN 2 ABSTRACT Randomized controlled trials have shown that a combination of vitamin D and calcium can prevent fragility fractures in the elderly. Whether this effect is attributed to the combination of vitamin D and calcium or to one of these nutrients alone is not known. We studied if an intervention with 10 g of vitamin D 3 per day could prevent hip fracture and other osteoporotic fractures in a double-blinded randomized controlled trial. Residents from 51 nursing homes were allocated randomly to receive 5 ml of ordinary cod liver oil (n 569) or 5 ml of cod liver oil where vitamin D was removed (n 575). During the study period of 2 years, fractures and deaths were registered, and the principal analysis was performed on the intention-to-treat basis. Biochemical markers were measured at baseline and after 1 year in a subsample. Forty-seven persons in the control group and 50 persons in the vitamin D group suffered a hip fracture. The corresponding figures for all nonvertebral fractures were 76 persons (control group) and 69 persons (vitamin D group). There was no difference in the incidence of hip fracture (p 0.66, log-rank test), or in the incidence of all nonvertebral fractures (p 0.60, log-rank test) in the vitamin D group compared with the control group. Compared with the control group, persons in the vitamin D group increased their serum 25-hydroxyvitamin D concentration with 22 nmol/liter (p 0.001). In conclusion, we found that an intervention with 10 g of vitamin D 3 alone produced no fracture-preventing effect in a nursing home population of frail elderly people. (J Bone Miner Res 2002;17: ) Key words: frail elderly, hip fracture, osteoporosis, randomized controlled trial, vitamin D INTRODUCTION HIP FRACTURE constitutes a large health problem in the elderly, and nursing home residents are especially prone to these fractures. (1,2) Vitamin D deficiency may be one important contributing risk factor for osteoporotic fracture in old people, partly because of reduced food intake, reduced sun exposure, and a decline in the capacity of producing vitamin D in the skin. (3) The authors have no conflict of interest. In observational studies, low vitamin D intake and status has been associated with increased risk of hip fracture, and intake of cod liver oil has been associated with reduced risk of hip fracture. (4,5) It also has been shown that vitamin D supplementation reduces bone loss from the femoral neck in postmenopausal women. (6,7) However, the effectiveness of vitamin D in the prevention of osteoporotic fractures is not clear. (8) In both a French and an American randomized controlled trial a combined intervention with vitamin D 3 and calcium significantly reduced the number of hip fractures (9) and the number of all nonvertebral fractures, (9,10) 1 National Health Screening Service, Oslo, Norway. 2 Institute for Nutrition Research, University of Oslo, Oslo, Norway. 3 Hormone Laboratory and Department of Internal Medicine, Aker University Hospital, Oslo, Norway. 709

2 710 MEYER ET AL. TABLE 1. BASELINE CHARACTERISTICS OF THE 1144 STUDY PARTICIPANTS Characteristic Control group (n 575) whereas in a Dutch randomized controlled trial supplementation with vitamin D 3 alone did not reveal a protective effect. (11) Further investigation is required to study whether vitamin D alone can prevent osteoporotic fractures. (8) The objective of this randomized controlled trial was to study the effectiveness (8,12) of vitamin D in the prevention of osteoporotic fractures in a population of frail elderly people, that is, would an intervention with 10 g of vitamin D 3 per day lead to reduced rates of hip fracture and all nonvertebral fractures in a large, unselected group of institutionalized elderly people compared with a similar placebo group. We also planned to do subgroup analyses to study the effect of vitamin D supplementation stratified on dietary calcium intake and vitamin D intake at baseline. MATERIALS AND METHODS Subjects (study population) Vitamin D group (n 569) Age (year) a Female (%) Weight (kg) a Height (cm) a BMI (kg/m 2 ) a Calcium intake from milk and cheese (mg) a Vitamin D supplementation (%) b Calcium supplementation (%) At least one fall during the last 3 months (%) Previous hip fracture (%) No Yes Do not know Dependent on gait support (%) No Yes, cane or crutch Wheelchair-user a Mean values SD. b At baseline, usually in the form of a multivitamin supplement. We aimed to include as many as possible of the nursing home residents in two Norwegian cities. Fifty-one out of 106 institutions were able and willing to participate. The participation rate at the individual institution was on average 22.4% and somewhat higher at the wards because, frequently, not all wards at the institutions participated. The study comprised 1144 residents. Mean age at baseline was 84.7 years (SD 7.4 years) and 75% of these were women (Table 1). To be eligible, the residents should have a life expectancy of more than half a year, should not be permanently bedridden, and should not have difficulties in taking medicine. Persons already taking vitamin D supplements (usually in the form of a multivitamin supplement) were included as long as this supplementation did not exceed 10 g/day. We found it unethical to require discontinuation of the supplementation in this population of frail elderly people. However, at the start of the study the use of vitamin D supplements was registered carefully. The study was approved by the regional ethics committee, Norwegian Board of Health and the Data Inspectorate. Oral consent was considered satisfactory for this study with cod liver oil, which has been used as a vitamin supplement in the Norwegian population for decades. As described elsewhere, (13) permission also was given to include mentally impaired persons in the study, a group that constitutes an important part of the nursing home population. Conduct of the trial and supplements The study started up at the different institutions over a 3-year period from autumn After careful instruction, the staff at the institutions included study participants. (13) Lists with all residents who were eligible and willing to participate were returned to the coordinating office. The intended complete record on those not included was not reported in a satisfactory way. Before the study started, the days of the month (1 31 days) were divided randomly into group A and group B, and based on the day of birth, a participant was placed automatically in group A or group B when registered in the study database. The nursing staff was not aware of the details in the allocation procedures. At baseline, a simple questionnaire was filled in for each participant by the nursing staff, including questions concerning calcium intake from cheese and milk, the use of vitamin D and calcium supplements, height and weight, previous hip fracture, fall during the preceding 3 months, and mobility status (use of cane, wheel chair, etc.). Cod liver oil is rich in vitamins D and A. Vitamin D given in oily suspensions generally is considered to be absorbed almost completely. Approximately 80% of this fat-soluble vitamin is incorporated into the chylomicron fraction and absorbed through the lymphatic system. (14) Cod liver oil also is a natural source of very long chain -3 fatty acids. The intervention was ordinary cod liver oil, whereas the placebo was ordinary cod liver oil in which vitamin D had been removed (Peter Møller, avd. av Orkla ASA, Oslo, Norway). Vitamin D was extracted from the cod liver oil using the techniques of bleaching earth, deodorization, and molecular distillation. Because vitamin A also was removed by this process, it was later added in the form of retinyl palmitate to obtain the same levels of vitamin A as in untreated cod liver oil. Retinyl palmitate is the naturally occurring form of vitamin A in cod liver oil. In the cod liver oil in which vitamin D was not removed, the levels of vitamins A and D were controlled by the producer. There were no differences in taste, smell, or color, and the levels of vitamin A, -3 fatty acids, and energy were similar in the two types of cod liver oil. Control analyses of the vitamin content by high-performance liquid chromatography

3 CAN VITAMIN D SUPPLEMENTATION PREVENT FRACTURE 711 showed trace amounts of vitamin D 3 in the treated cod liver oil ( g/ml) compared with 2.2 g/ml in the untreated, that is, a difference of 10 g per 5-ml dose. During the 2 year study period, the intervention group received 5 ml ordinary cod liver oil daily, whereas the control group received 5 ml cod liver oil daily in which vitamin D had been removed. The individual participants either received group A cod liver oil or group B cod liver oil. The study was double-blinded because neither the participants nor the nursing staff or the investigators were aware of which group contained vitamin D. In general, the daily dose of cod liver oil was delivered together with other medicines by the staff. A person from the coordinating office visited each ward several times during the study and had regular contact by telephone. Follow-up All participants were followed with respect to hip fractures, other nonvertebral fractures, and death during the 2-year study period. (13) Only fractures verified via hospital discharge letters or X-ray descriptions were included in the analysis. Follow-up with respect to fractures also was done for withdrawals. At the end of the study, vital status (and date of death when applicable) for all participants was checked in the Norwegian registry of vital statistics. To validate the reporting of hip fractures at the institutions and to ensure a complete follow-up, the computerized discharge registers in all hospitals serving the included institutions were checked against the study database to see if participants were admitted for hip fractures. Unverified hip fractures were confirmed in the participant s medical records at the hospitals. The person responsible for this checking was not otherwise involved in the study and had no knowledge about the study participants. 22 hip fractures were identified in this way, which constitute 22.5% of all identified hip fractures. We were not able to follow 26 participants for all fractures when they moved to other institutions. However, they were followed for hip fracture using hospital registers. When withdrawal occurred, the active-treatment period was from the date at entry to the date of withdrawal. Biochemical measurements Because the Data Inspectorate required written consent from all persons in whom a blood sample was drawn, mentally impaired persons were excluded from this procedure. In general, it was difficult to recruit persons for blood tests, and we ended up with a smaller than intended group, which was on average 2.2 years younger (p 0.02) and had a lower mortality during the study period (p 0.000) compared with the rest. The blood samples were analyzed for 25-hydroxyvitamin D (calcidiol), osteocalcin, parathyroid hormone (PTH), and ionized calcium. All analyses were performed by the Hormone Laboratory, Aker Hospital, Oslo, Norway. The methods are described elsewhere. (15) The blood samples were drawn at baseline and at 1 year after the study started ( 1 month), regardless of whether they still took the treatment or not. Statistical analyses Based on previous studies, (5,13,16) we conservatively estimated that 6% of the nursing home population of Oslo sustained a new hip fracture annually. A sample size of 1113 participants in each group thus would give the study 80% power to detect a reduction in hip fracture incidence by 30% at the 5% significance level. If hip fractures constitute 50% of all nonvertebral fractures in such a population, (9) the study would have similar power to detect a 20% reduction in all nonvertebral fractures. Differences between the two groups in baseline characteristics and in treatment status were tested by the 2 test for categorical variables and by the independent samples t-test for means. Concerning changes in biochemical markers from baseline to year 1, differences between the two groups were tested by the independent samples t-test. In those instances in which the criteria for normal distribution were not fulfilled, the variables were log-transformed, and the significance test was repeated. Because they gave similar results, they were not reported. Two types of fracture endpoints were defined in the protocol: hip fracture (defined as cervical or trochanteric fracture) and all nonvertebral fractures (including hip fracture). The principal analysis of fracture data was made on the intention-to-treat basis (12) using Kaplan-Meier analyses. The two groups were compared by the log-rank test. (12) Unadjusted and multivariate-adjusted hazard rate ratios, in the text called relative risks, were calculated by the Cox proportional hazards regression. In the multivariate model controlling for potential confounding variables, all variables listed in Table 1 except weight and height were included. Censoring of data occurred only for people who died and people lost to follow-up. Because of matching to hospital registers, we had a complete follow-up of hip fracture. Active-treatment analysis also was performed wherein all persons were followed as long as they took the cod liver oil. The two groups were compared by the log-rank test. Finally, an analysis including only the people treated and followed for the whole study period was undertaken, comparing the two groups by the 2 test. The effects of the intervention on fractures and biochemical tests were evaluated before unblinding of the data. In the protocol it also was planned to do subgroup analyses stratifying on total calcium intake from cheese and milk as registered in the questionnaire at the start of the study (higher or lower than median intake of 400 mg/day) and the use of vitamin D supplements at the start of the study (yes/no). People treated for the whole study period were labeled treated for 2 years. This group also includes 34 persons who were included so late that they had not participated for 2 years when the study ended in the summer of RESULTS Five-hundred seventy-five residents were allocated to the control group and 569 residents were allocated to the vitamin D group. There were no statistically significant differ-

4 712 MEYER ET AL. TABLE 2. TREATMENT STATUS (1144 PARTICIPANTS) Control group n (%) Vitamin D group n (%) Treated for 2 years 186 (32.3) 197 (34.6) Cessation of treatment Death a 163 (28.3) 169 (29.7) Other reasons b,c 226 (39.3) 203 (35.7) Total a Treated on average 10.2 months. b Treated on average 9 months. c Reasons for cessation of treatment: no longer wanted to receive the treatment (n 184); the ward discontinued to participate in the study (n 87); the participant stopped taking the treatment because of illness; poor appetite; nausea, etc. (n 117); the participant not taking vitamin D supplements at entry started to take vitamin D supplements during the study (n 7); the participant moved to an other institution (n 26). For 8 persons the exact reason for withdrawal was not stated. ences between the two groups in baseline characteristics (Table 1). Of those included in the study, 383 persons received cod liver oil throughout the study period, 332 persons discontinued the treatment because of death (after an average treatment period of 10.2 months), and 429 persons stopped taking the treatment for a variety of other reasons (after an average treatment period of 9 months; Table 2). Of these 429 persons, 159 died after they had stopped taking the treatment and before end of follow-up. There was no difference in mortality between the control group and the vitamin D group (p 0.87, log-rank test), and there was no significant difference in the proportions who stopped taking the treatment for other reasons and in the proportions who were treated for 2 years. The study participants were followed for 1728 person-years (intention-to-treat), and they received cod liver oil for a period of 1365 person-years or in 79% of the observation time. Results from serum biochemical tests at baseline and after 1 year are shown in Table 3. One-third had a serum concentration of 25-hydroxyvitamin D 30 nmol/liter, and 15% had 20 nmol/liter at baseline. During the first year of the study, persons in the intervention group increased their 25-hydroxyvitamin D concentration by 22 nmol/liter (95% CI, ) compared with the control group. There was no statistical significant difference between the two groups concerning change in serum PTH, serum ionized calcium, or serum osteocalcin. During follow-up, 99 hip fractures were identified in 97 persons and 169 nonvertebral fractures (hip fractures included) were identified in 145 persons. Forty-seven persons in the control group and 50 persons in the vitamin D group suffered a hip fracture. The corresponding figures for all nonvertebral fractures were 76 persons in the control group and 69 persons in the vitamin D group (Table 4). There was no difference in the incidence of hip fracture between the control group and the vitamin D group according to the intention-to-treat analysis (Fig. 1). The relative risk of hip fracture in the vitamin D group versus the control group was 1.09 (95% CI, ), and multivariate adjustment did not change this estimate. Similar results were found for active-treatment analysis (p 0.55, log-rank test) and in the analysis restricted to participants treated for the whole study period (p 0.97, 2 test). There was no effect of the intervention with vitamin D on all nonvertebral fractures (Fig. 1). Thus, the relative risk of any nonvertebral fracture was 0.92 (95% CI, ) in the vitamin D group versus the control group, and multivariate adjustment had negligible effect on the estimate. Similar results were found for active-treatment analysis (p 0.67, log-rank test) and in the analysis restricted to participants treated for the whole study period (p 0.41, 2 test). Concerning hip fracture, subgroup analyses showed that an effect of the intervention with vitamin D was evident neither in those with a higher than median intake (p 0.60, log-rank test) nor in those with a lower than median intake of calcium at baseline (p 0.31, log-rank test). Likewise, there was no effect in those not taking (p 0.18, log-rank test) or in those taking (p 0.30, log-rank test) a vitamin D supplement at the start of the study. Similar results were found for all nonvertebral fractures. For example, in those not taking vitamin D supplements at baseline, 42 persons in the control group and 40 persons in the vitamin D group were identified with any nonvertebral fracture during follow-up, with a corresponding relative risk of 0.93 (95% CI, , vitamin D group vs. control group). DISCUSSION In this study, performed in a population of frail nursing home residents, an intervention with 10 g (400 IU) of vitamin D neither prevented hip fracture nor all nonvertebral fractures. Subgroup analyses stratified on dietary calcium intake and vitamin D intake at baseline gave similar results. Our study is in concert with a large Dutch randomized controlled trial intervening with 10 g of vitamin D/day alone as tablets over years in a somewhat healthier study population than ours (mean age, 80 years; participants living independently, in apartments or homes for the elderly). (11) In contrast to the lack of effect of vitamin D alone reported in these studies, a fracturepreventing effect of an intervention with vitamin D and calcium combined has been reported in a large French randomized controlled trial over 18 months (9) and a smaller American randomized controlled trial over 3 years. (10) The participants in the French study were institutionalized and on average 84 years old, whereas the participants in the American study were on average 71 years old and were living in the community. In both studies, a higher dose of vitamin D was used ( g/day), and the calcium supplementation ranged from 500 to 1200 mg/day. Although it cannot be excluded that the higher vitamin D dose is responsible for these differences, a study in elderly women and men showed that a daily supplementation with 10 g of vitamin D clearly increased 25-hydroxyvitamin D in serum, whereas only a marginal additional effect was seen in those randomized to receive a dose of 20 g/day. (17)

5 CAN VITAMIN D SUPPLEMENTATION PREVENT FRACTURE 713 TABLE 3. SERUM BIOCHEMICAL VALUES IN THE CONTROL GROUP AND VITAMIN DGROUP AT BASELINE AND AFTER 1YEAR A Baseline 1 Year Change (1 year baseline) Serum 25-hydroxyvitamin D (nmol/liter) Control group (n 31) Vitamin D group (n 34) * Serum PTH (pmol/liter) Control group (n 34) Vitamin D group (n 36) Serum ionized calcium (mmol/liter) Control group (n 26) Vitamin D group (n 31) Serum osteocalcin (nmol/liter) Control group (n 33) Vitamin D group (n 35) a Mean values SD. * p for the comparison between the study groups. TABLE 4. NUMBER OF FIRST HIP FRACTURE AND NUMBER OF FIRST NONVERTEBRAL FRACTURE a IN THE 1144 STUDY PARTICIPANTS Control group Vitamin D group Hip fracture b All nonvertebral fractures Radius or ulna 7 3 Proximal humerus 7 8 Hip b Other a In addition, 16 persons had two fractures and 4 persons had three fractures. b Two persons in the control group and 3 persons in the vitamin D group had a fracture other than hip fracture first. Approximately 80% of the participant in our study lived in Oslo, Norway, the city with the highest incidence rates of hip fracture ever reported internationally. (16) It has been estimated that the annual incidence of hip fracture in the nursing home population of Oslo exceeds 7 per 100 per year. (13) The incidence in our study population was 5.9 per 100 per year, which is twice as high as in the Dutch study by Lips et al., (11) and also higher than in the French study by Chapuy et al. (9) In this frail population with a very high risk of fracture, we did not find any effect of the intervention with 10 g of vitamin D. On the other hand, 40% of the participants took vitamin D supplements (usually in the form of multivitamin supplements containing 10 g of vitamin D) at baseline. However, there was no indication of a different effect of the intervention in those not taking supplements compared with those taking supplements at baseline. Previous studies in Oslo, Norway have suggested that poor vitamin D status in the elderly is prevalent and that low vitamin D intake is associated with increased risk of hip fracture. (5,18) On the other hand, a recent study performed in three nursing homes in Oslo, of which two participated in our study, reported a median nutritional intake of vitamin D of 4.5 g/day in women and 5.3 g/day in men, and that additional supplementation with vitamin D was frequent. (19) The serum 25-hydroxyvitamin D concentrations at baseline in our subsample also suggest that serious vitamin D deficiency was not very frequent in our study population. However, because we were not able to take blood tests on a random sample of all participants, we cannot exclude the possibility that the blood test subsample, which was somewhat younger and had lower mortality, had better vitamin D status than the rest of the study population. It also should be added that it might be problematic to compare 25- hydroxyvitamin D levels in this study with other studies because of interlaboratory variation. (20) Serum 25-hydroxyvitamin D increased in the vitamin D group compared with the control group. However, we did not find a corresponding decrease in PTH, and the reason for this can only be speculated on. We did not measure renal function or 1,25-dihydroxyvitamin D, the metabolite acting directly on the parathyroid gland. It was of great importance to design a study that was workable and demanded little extra effort from the nursing staff because much of the practical work was carried out by the employees at the large number of participating institutions. Therefore, the practical procedures were as simple as possible. Because milk and cheese constitute two-thirds of the total calcium intake in an average Norwegian diet, (13) calcium intake was estimated based on a few questions on milk and cheese intake. Therefore, the categorization of the participants into high/low intake might be subject to nondifferential misclassification, which could reduce the effect of calcium in the analyses. Because cod liver oil also contains vitamin A, both the control group and the vitamin D group received vitamin A (0.26 mg/ml). For a long time, it has been suggested that high intake of vitamin A is harmful for skeletal health, and, recently, (after the start of this study) it has been questioned whether an adverse effect also might be present at moder-

6 714 MEYER ET AL. FIG. 1. Cumulative percentage with (A) incident hip fracture and (B) nonvertebral fracture in the control group and in the vitamin D group. Intention-to-treat analyses. ately increased intakes. (21,22) On the other hand, in a recent randomized controlled trial, one group received calcium and vitamin D and the other received calcium and vitamin D as a multivitamin formulation including 0.8 mg of retinol. (23) No difference between the two groups, regarding bone mineral density (BMD) of the spine or hip, was found. In our study, the incidence of hip fracture was lower than the estimated incidence in the general nursing home population, which does not support a deleterious skeletal effect of the supplemented vitamin A. Our method of randomization by day of birth may be defined as quasi-randomization. (8) However, because it was double-blinded which group received the vitamin D cod liver oil, it is difficult to see how our procedure of randomization could introduce selection bias. Concerning concealment of allocation, no judgment was made either by the nursing staff or by anyone at the coordinating office on whether a person should participate or not in light of which group he or she belonged to. The only potentially serious problem concerning our allocation procedure, as far as we see it, was that because of the open grouping of participants, nursing staff, etc. could get the impression that one of the groups was doing better than the other and that such anticipation would lead to different treatment and follow-up. However, usually, the number of participants at each ward was small, making comparison less likely. At the coordinating office, data collection from the institutions and evaluation of fractures were done by different persons. In addition, the identification of fractures via the computerized discharge registers at the hospitals enabled us to validate the recording of hip fractures at the institutions independently. Concerning compliance, the nursing staff was instructed to register when and why a participant stopped taking the treatment. This also was asked for when a person from the coordinating office visited each ward several times during the study. In a survey made at the end of the study at 63 of the participating wards, 95% of the wards stated that the participants had received the treatment regularly. (13) The change in 25-hydroxyvitamin D also indicated an effect of the intervention. Originally, the study was planned to include nursing homes only in Oslo, Norway. In spite of hard effort, the recruitment was lower than anticipated, and the study was expanded to include nursing home residents in Bergen, the second largest city in Norway, and in Lier, a neighboring municipality to Oslo. Even so, our primary goal of including 2250 participants was unrealistic. The closing date for treatment was set to June 30, It could be argued that we might have missed a clinical interesting difference because of reduced power. On the other hand, the lack of any suggestion of effect in this study and in the study from Amsterdam strongly suggests that an intervention with 10 g of vitamin D alone does not have a substantial fracturepreventive effect. It should be added that serious vitamin D deficiency was uncommon in these two study populations, and the results do not rule out the possibility of a fracturepreventing effect of an intervention with vitamin D alone in elderly individuals with poor vitamin D status. In conclusion, in this randomized controlled trial we did not find that an intervention with 10 g of vitamin D over 2 years could prevent hip fracture and other osteoporotic fractures in institutionalized elderly people. ACKNOWLEDGMENTS We thank Thale Briseid and Anne-Marie Aas for their contribution in the preparation of the study, Hilde and Roger Antonsen for contribution in the data collection, Egil Haug who was responsible for the blood analyses, Cathrine Lofthus who checked the computerized discharge registers for hip fracture, and the nursing staff and nursing home residents who participated in the study. The trial was economically supported by Peter Møller, avd. av Orkla ASA, Norwegian Dairies, the City Council of Oslo, and Odd Fellow. Cod liver oil was donated by Peter Møller, avd. av Orkla ASA, Oslo, Norway. REFERENCES 1. Johnell O, Sernbo I 1986 Health and social status in patients with hip fractures and controls. Age Ageing 15:

7 CAN VITAMIN D SUPPLEMENTATION PREVENT FRACTURE Cumming RG 1996 Nursing home residence and risk of hip fracture. Am J Epidemiol 143: Feldman D, Malloy PJ, Gross C 1996 Vitamin D: Metabolism and action. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp Falch JA, Mowe M, Bøhmer T, Haug E 1992 Serum levels of intact parathyroid hormone in elderly patients with hip fracture living at home. Acta Endocrinol (Copenh) 126: Meyer HE, Henriksen C, Falch JA, Pedersen JI, Tverdal A 1995 Risk factors for hip fracture in a high incidence area: A case-control study from Oslo, Norway. Osteoporos Int 5: Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P 1995 Prevention of bone loss by vitamin D supplementation in elderly women: A randomized doubleblind trial. J Clin Endocrinol Metab 80: Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, Falconer G, Green CL 1995 Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr 61: Gillespie WJ, Henry DA, O Connell DL, Robertson J 1997 Vitamin D and vitamin D analogues in the prevention of fractures in involutional and post-menopausal osteoporosis. In: Gillespie WJ, Madhok R, Swiontkowski M, Robinson CM, Murray GD (eds.) Musculoskeletal Injuries Module of The Cochrane Database of Systematic Reviews. The Cochrane Collaboration, Issue 2. Oxford University Press, London, UK. 9. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ 1992 Vitamin D 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327: Dawson-Hughes B, Harris SS, Krall EA, Dallal GE 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM 1996 Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 124: Pocock SJ 1991 Clinical Trials. A Practical Approach. John Wiley & Sons, Chichester, UK. 13. Kvaavik E, Meyer HE, Smedshaug GB, Falch JA, Tverdal A, Pedersen JI 2000 The intervention study Prevention of Hip Fractures. Method and implementation. Nor J Epidemiol 10: Holick MF 1998 Vitamin D: Intestinal absorption. In: Shils ME, Olson JA, Shike M (eds.) Modern Nutrition in Health and Disease. Lea & Febiger, Philadelphia, PA, USA, pp Falch JA, Steihaug S 2000 Vitamin D deficiency in Pakistani premenopausal women living in Norway is not associated with evidence of reduced skeletal strength. Scand J Clin Lab Invest 60: Falch JA, Kaastad TS, Bohler G, Espeland J, Sundsvold OJ 1993 Secular increase and geographical differences in hip fracture incidence in Norway. Bone 14: Lips P, Wiersinga A, van Ginkel FC, Jongen MJ, Netelenbos JC, Hackeng WH, Delmas PD, van der Vijgh WJ 1988 The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 67: Mowe M, Bohmer T, Haug E 1998 Vitamin D deficiency among hospitalized and home-bound elderly. Tidsskr Nor Laegeforen 118: Kvaavik E 1997 En forundrsøkelse til prosjektet Forebyggelse av lårhalsbrudd. Inntak av kalsium og vitamin D på sykehjem i Oslo. Institute for Nutrition Research, University of Oslo, Oslo, Norway. 20. Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF 1999 An international comparison of serum 25- hydroxyvitamin D measurements. Osteoporos Int 9: Melhus H, Michaelsson K, Kindmark A, Bergstrom R, Holmberg L, Mallmin H, Wolk A, Ljunghall S 1998 Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med 129: Binkley N, Krueger D 2000 Hypervitaminosis A and bone. Nutr Rev 58: Bæksgaard L, Andersen KP, Hyldstrup L 1998 Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. Osteoporos Int 8: Address reprint requests to: Haakon Eduard Meyer, M.D., Ph.D. Norwegian Institute of Public Health P.O. Box 4404 Nydalen 0403 Oslo, Norway Received in original form January 2, 2001; in revised form April 9, 2001; accepted June 21, 2001.

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People

Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,

More information

Vitamin D Status of an Outpatient Clinic Population

Vitamin D Status of an Outpatient Clinic Population Calcif Tissue Int (2001) 69:263 267 DOI: 10.1007/s002230010054 2001 Springer-Verlag New York Inc. Vitamin D Status of an Outpatient Clinic Population L. Margiloff, 1 S. S. Harris, 2 S. Lee, 3 R. Lechan,

More information

Closing the Care Gap in Osteoporosis ICE Conference 2015

Closing the Care Gap in Osteoporosis ICE Conference 2015 Closing the Care Gap in Osteoporosis ICE Conference 2015 Pat McCarthy-Briggs RD, MHEd Thank You! What is osteoporosis? a systemic skeletal disease characterized by low bone mass and microarchitectural

More information

V t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s

V t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s Vitamin D and Calcium: Role in Prevention and Treatment of Fractures and Falls Osteoporosis 21: New Insights In Research, Diagnosis, and Clinical Care Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic

More information

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals

More information

Vitamin D for the Prevention of Osteoporotic Fractures

Vitamin D for the Prevention of Osteoporotic Fractures TITLE: Vitamin D for the Prevention of Osteoporotic Fractures AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department of Medicine University of California

More information

Robin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson

Robin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson The skeletal benefits of calcium- and vitamin D 3 fortified milk are sustained in older men after withdrawal of supplementation: an 18-mo follow-up study 1 3 Robin M Daly, Nicole Petrass, Shona Bass, and

More information

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:

More information

Objectives. Polypharmacy Seminar. Causes of Polypharmacy. Polypharmacy 8/05/12. National Prescribing Curriculum Module

Objectives. Polypharmacy Seminar. Causes of Polypharmacy. Polypharmacy 8/05/12. National Prescribing Curriculum Module Polypharmacy Seminar Objectives On completion of this module you should be able to: state the major guiding principles in rational prescribing recognise, and substantiate, over-prescribing or inappropriate

More information

Vitamin D and Calcium

Vitamin D and Calcium Vitamin D and Calcium American Association of Clinical Endocrinologists Marina Del Rey, CA September 15, 2018 Albert Shieh, MD MS Assistant Clinical Professor Department of Medicine Division of Endocrinology

More information

The Auckland calcium study: 5-year post-trial follow-up

The Auckland calcium study: 5-year post-trial follow-up Osteoporos Int (2014) 25:297 304 DOI 10.1007/s00198-013-2526-z ORIGINAL ARTICLE The Auckland calcium study: 5-year post-trial follow-up L. T. Radford & M. J. Bolland & B. Mason & A. Horne & G. D. Gamble

More information

ORIGINAL ARTICLE. R. A. Lyons & A. Johansen & S. Brophy & R. G. Newcombe & C. J. Phillips & B. Lervy & R. Evans & K. Wareham & M. D.

ORIGINAL ARTICLE. R. A. Lyons & A. Johansen & S. Brophy & R. G. Newcombe & C. J. Phillips & B. Lervy & R. Evans & K. Wareham & M. D. Osteoporos Int (2007) 18:811 818 DOI 10.1007/s00198-006-0309-5 ORIGINAL ARTICLE Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one

More information

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008 BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology

More information

Coordinator of Post Professional Programs Texas Woman's University 1

Coordinator of Post Professional Programs Texas Woman's University 1 OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,

More information

Helpful information about bone health & osteoporosis Patient Resource

Helpful information about bone health & osteoporosis Patient Resource Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half

More information

BONE HEALTH BASICS. Promoting Healthy Bones: Sorting Out the Science. Learning Objectives. Guest Speaker

BONE HEALTH BASICS. Promoting Healthy Bones: Sorting Out the Science. Learning Objectives. Guest Speaker Copyright 11 by the Preventive Cardiovascular Nurses Association Promoting Healthy Bones: Sorting Out the Science Guest Speaker Robert P. Heaney, MD, FACP, FASN Professor and Professor of Medicine Creighton

More information

Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones

Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones Prepared by Annette Dickinson, Ph.D. Council for Responsible Nutrition June 2002 There is no question that a generous intake of

More information

Osteoporosis a bone disorder

Osteoporosis a bone disorder Osteoporosis-Related Hip Fractures Cost $13 Billion to $18 Billion Yearly Eric Barefield (404) 880-6289 Osteoporosis a bone disorder associated with increased susceptibility to fracture of the hip, spine,

More information

A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention

A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention Heike A. Bischoff-Ferrari, M.D., Dr.P.H., Walter C. Willett,

More information

Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D 3. ) for prevention of fractures in primary care

Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D 3. ) for prevention of fractures in primary care Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D 3 ) for prevention of fractures in primary care Jill Porthouse, Sarah Cockayne, Christine King, Lucy Saxon, Elizabeth

More information

Elecsys bone marker panel. Optimal patient management starts in the laboratory

Elecsys bone marker panel. Optimal patient management starts in the laboratory bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic

More information

A lmost 100% of hip fractures are the result of a fall.1 2

A lmost 100% of hip fractures are the result of a fall.1 2 16 ORIGINAL ARTICLE Risk of hip fracture in protected and unprotected falls in nursing homes in Norway L Forsén, A J Søgaard, S Sandvig, A Schuller, U Røed, C Arstad... See end of article for authors affiliations...

More information

Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents

Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents Osteoporos Int (2008) 19:663 671 DOI 10.1007/s00198-007-0465-2 ORIGINAL ARTICLE Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing

More information

N orway has one of the highest incidences of hip fracture

N orway has one of the highest incidences of hip fracture 344 ORIGINAL ARTICLE Compliance with external hip protectors in nursing homes in Norway L Forsén, S Sandvig, A Schuller, A J Søgaard... See end of article for authors affiliations... Correspondence to:

More information

Name of Policy: Boniva (Ibandronate Sodium) Infusion

Name of Policy: Boniva (Ibandronate Sodium) Infusion Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews

More information

Executive summary. Executive summary 11. Effects and sources of vitamin D

Executive summary. Executive summary 11. Effects and sources of vitamin D Executive summary Dietary reference values indicate the ideal amount of a given substance for daily intake in order to stay healthy. The Health Council of the Netherlands regularly checks whether the existing

More information

1

1 www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:

More information

NIH Public Access Author Manuscript Osteoporos Int. Author manuscript; available in PMC 2011 January 8.

NIH Public Access Author Manuscript Osteoporos Int. Author manuscript; available in PMC 2011 January 8. NIH Public Access Author Manuscript Published in final edited form as: Osteoporos Int. 2011 January ; 22(1): 345 349. doi:10.1007/s00198-010-1179-4. Does Dietary Protein Reduce Hip Fracture Risk in Elders?

More information

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department

More information

The New England Journal of Medicine EFFECT OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER

The New England Journal of Medicine EFFECT OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER EFFECT OF CALCIUM AND VITAMIN D SULEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER BESS DAWSON-HUGHES, M.D., SUSAN S. HARRIS, D.SC., ELIZABETH A. KRALL, H.D., AND GERARD E. DALLAL,

More information

Tymlos (abaloparatide) NEW PRODUCT SLIDESHOW

Tymlos (abaloparatide) NEW PRODUCT SLIDESHOW Tymlos (abaloparatide) NEW PRODUCT SLIDESHOW Introduction Brand name: Tymlos Generic name: Abaloparatide Pharmacological class: Human parathyroid hormone related peptide analog Strength and Formulation:

More information

NICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield

NICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield NICE SCOOP OF THE DAY FRAX with NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Consultant/Advisor/Speaker for: o ActiveSignal, Amgen, AstraZeneca, Consilient

More information

The Risks of Hip Fracture in Older People from Private Homes and Institutions

The Risks of Hip Fracture in Older People from Private Homes and Institutions Age and Ageing 1996:25:381-385 The Risks of Hip Fracture in Older People from Private Homes and Institutions MEG BUTLER, ROBYN NORTON, TREVOR LEE-JOE, ADA CHENG, A. JOHN CAMPBELL Summary This study aimed

More information

Men and Osteoporosis So you think that it can t happen to you

Men and Osteoporosis So you think that it can t happen to you Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School

More information

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits

More information

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:

More information

The prevalence and history of knee osteoarthritis in general practice: a case control study

The prevalence and history of knee osteoarthritis in general practice: a case control study The Author (2005). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org doi:10.1093/fampra/cmh700 Family Practice Advance Access

More information

Prevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University Hospital, Ojha Campus. A Cross Sectional Study

Prevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University Hospital, Ojha Campus. A Cross Sectional Study ISPUB.COM The Internet Journal of Nutrition and Wellness Volume 12 Number 1 Prevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University S Shukar-ud-din, R Tabassum,

More information

CFDR Semi Annual Research Showcase May 1st, 2014

CFDR Semi Annual Research Showcase May 1st, 2014 CFDR Semi Annual Research Showcase May 1st, 2014 Source: Canada s Aging Population, Health Canada, 2002, p. 3 s The 2006 Census revealed that 4.3 million Canadians were > 65 y Almost 7% lived in health

More information

Management of postmenopausal osteoporosis

Management of postmenopausal osteoporosis Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,

More information

Vitamin D during pregnancy and breastfeeding

Vitamin D during pregnancy and breastfeeding Vitamin D during pregnancy and breastfeeding Getting the right nutrients and eating well when you re pregnant or breastfeeding is important for your baby s growth and development. Vitamin D helps you to

More information

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014 HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research

More information

H. Smith, F. Anderson 1, H. Raphael, P. Maslin, S. Crozier 2 and C. Cooper 2. Methods Study design. Introduction. Recruitment and randomization

H. Smith, F. Anderson 1, H. Raphael, P. Maslin, S. Crozier 2 and C. Cooper 2. Methods Study design. Introduction. Recruitment and randomization Rheumatology 7;46:185 1857 Advance Access publication 1 November 7 doi:1.193/rheumatology/kem4 Effect of annual intramuscular vitamin D on fracture risk in elderly men and women a population-based, randomized,

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bolland MJ, Grey A, Gamble GD, Reid IR. The

More information

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy

More information

MEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY

MEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY MEDICAL POLICY SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY A nonprofit independent licensee of the BlueCross BlueShield Association PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not

More information

Postmenopausal osteoporosis is a systemic

Postmenopausal osteoporosis is a systemic OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility

More information

NIH Public Access Author Manuscript J Am Coll Nutr. Author manuscript; available in PMC 2009 August 20.

NIH Public Access Author Manuscript J Am Coll Nutr. Author manuscript; available in PMC 2009 August 20. NIH Public Access Author Manuscript Published in final edited form as: J Am Coll Nutr. 2008 April ; 27(2): 274 279. Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older

More information

Clinical Policy: Measurement of Serum 1,25-dihydroxyvitamin D

Clinical Policy: Measurement of Serum 1,25-dihydroxyvitamin D Clinical Policy: Reference Number: CP.MP.152 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

Risedronate prevents hip fractures, but who should get therapy?

Risedronate prevents hip fractures, but who should get therapy? INTERPRETING KEY TRIALS CHAD L. DEAL, MD Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic THE HIP TRIAL Risedronate prevents

More information

DRI Concept. DRI Concept

DRI Concept. DRI Concept Risk of adverse effects 1.5 0 DRI Concept DRI Concept EAR RDA UL 1.5 0 Observed level intake Risk of inadequacy Tolerable Upper Intake Level The highest level of daily nutrient intake that is likely to

More information

Update on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA

Update on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes

More information

Letters to the Editor

Letters to the Editor Letters to the Editor Do we really need 100 g vitamin D/d, and is it safe for all of us? Vieth et al (1) regard a daily intake of 100 g (4000 IU) vitamin D 3 necessary to ensure desirable 25(OH)D [25-

More information

The NOF & NBHA Quality Improvement Registry

The NOF & NBHA Quality Improvement Registry In collaboration with CECity The NOF & NBHA Quality Improvement Registry This registry is approved by CMS as a Qualified Clinical Data Registry (QCDR) for Eligible Professionals and GPRO Practices for

More information

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

OSTEOPOROSIS: PREVENTION AND MANAGEMENT OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring

More information

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee

More information

B3D-MC-GHCY Clinical Study Report Synopsis Page 1Page GHCY Synopsis LY

B3D-MC-GHCY Clinical Study Report Synopsis Page 1Page GHCY Synopsis LY B3DMCGHCY Clinical Study Report Page 1Page 1 2. GHCY B3DMCGHCY Clinical ClinicalStudy StudyReport Report Page 2Page 2 Clinical Study Report : Study B3DMCGHCY Title of Study: The Effect of Teriparatide

More information

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS 4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending

More information

MS Society of Canada Recommendations on Vitamin D in MS 1

MS Society of Canada Recommendations on Vitamin D in MS 1 MS Society of Canada Recommendations on Vitamin D in MS Many people affected by MS have questions about vitamin D, and whether it can prevent MS or be used to help stop the disease from getting worse.

More information

VITAMIN D ACTS THROUGH several pathways to influence

VITAMIN D ACTS THROUGH several pathways to influence JOURNAL OF BONE AND MINERAL RESEARCH Volume 22, Supplement 2, 2007 doi: 10.1359/JBMR.07S209 2007 American Society for Bone and Mineral Research Therapy of Osteoporosis With Calcium and Vitamin D Bess Dawson-Hughes

More information

The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake

The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake Korean J Fam Med. 2013;34:43-48 http://dx.doi.org/10.4082/kjfm.2013.34.1.43 The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake Original Article Junga Kim, Byungsung

More information

Vitamin K intake and bone mineral density in women and men 1 4

Vitamin K intake and bone mineral density in women and men 1 4 Vitamin K intake and bone mineral density in women and men 1 4 Sarah L Booth, Kerry E Broe, David R Gagnon, Katherine L Tucker, Marian T Hannan, Robert R McLean, Bess Dawson-Hughes, Peter WF Wilson, L

More information

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of

More information

Who should receive calcium and vitamin D supplementation?

Who should receive calcium and vitamin D supplementation? Age and Ageing Advance Access published August 8, 2012 Age and Ageing 2012; 0: 1 5 The Author 2012. Published by Oxford University Press on behalf of the British Geriatrics Society. doi: 10.1093/ageing/afs094

More information

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr. Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many

More information

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage

More information

The Association between Vitamin D and Lung Cancer Risk in Finnish Male Smokers. Julia Burkley Briarcliff High School

The Association between Vitamin D and Lung Cancer Risk in Finnish Male Smokers. Julia Burkley Briarcliff High School The Association between Vitamin D and Lung Cancer Risk in Finnish Male Smokers. Julia Burkley Briarcliff High School 2 Burkley Table of Contents Introduction~ Pg. 2 Methods~ Pg. 4 Ethics Statement~ Pg.

More information

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

THE IMPORTANCE OF ADEQUATE

THE IMPORTANCE OF ADEQUATE ORIGINAL CONTRIBUTION Relationship Between Serum Parathyroid Hormone Levels, Vitamin D Sufficiency, and Calcium Intake Laufey Steingrimsdottir, PhD Orvar Gunnarsson, MD Olafur S. Indridason, MD, MHS Leifur

More information

Clinical Policy: Abaloparatide (Tymlos) Reference Number: CP.CPA.306 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Abaloparatide (Tymlos) Reference Number: CP.CPA.306 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Tymlos) Reference Number: CP.CPA.306 Effective Date: 06.13 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

MILK. Nutritious by nature. The science behind the health and nutritional impact of milk and dairy foods

MILK. Nutritious by nature. The science behind the health and nutritional impact of milk and dairy foods MILK Nutritious by nature The science behind the health and nutritional impact of milk and dairy foods Weight control Contrary to the popular perception that dairy foods are fattening, a growing body of

More information

Increased mortality after fracture of the surgical neck of the humerus: a case-control study of 253 patients with a 12-year follow-up.

Increased mortality after fracture of the surgical neck of the humerus: a case-control study of 253 patients with a 12-year follow-up. Increased mortality after fracture of the surgical neck of the humerus: a case-control study of 253 patients with a 12-year follow-up. Olsson, Christian; Petersson, Claes; Nordquist, Anders Published in:

More information

FOR CONSUMERS AND PATIENTS

FOR CONSUMERS AND PATIENTS AVAILABILITY OF VITAMIN D FOR CONSUMERS AND PATIENTS Prof. Heike A. Bischoff-Ferrari, MD, DrPH Centre on Aging and Mobility, University of Zurich Dept. of Rheumatology, University Hospital Zurich Overview

More information

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series

More information

Assessment of Musculoskeletal Pain among Patients with Vitamin D Deficiency

Assessment of Musculoskeletal Pain among Patients with Vitamin D Deficiency Original article: Assessment of Musculoskeletal Pain among Patients with Vitamin D Deficiency Dr. Devendra Kumar Kundara Junior Specialist (General Medicine), D.B. Hospital, Churu, Rajasthan, India. Corresponding

More information

Osteoporosis is a disease in which bones become fragile

Osteoporosis is a disease in which bones become fragile Preventing Osteoporosis the Bone Estrogen Strength Training Way by Linda B. Houtkooper, Ph.D., R.D., FACSM, Vanessa A. Stanford, M.S., R.D., CSCS, Lauve L. Metcalfe, M.S., FAWHP, Timothy G. Lohman, Ph.D.,

More information

NIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.

NIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11. NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk

More information

Differentiating Pharmacological Therapies for Osteoporosis

Differentiating Pharmacological Therapies for Osteoporosis Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking

More information

A response by Servier to the Statement of Reasons provided by NICE

A response by Servier to the Statement of Reasons provided by NICE A response by Servier to the Statement of Reasons provided by NICE Servier gratefully acknowledges the Statement of Reasons document from NICE, and is pleased to provide information to assist NICE in its

More information

Calcium metabolism and the Parathyroid Glands. Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands

Calcium metabolism and the Parathyroid Glands. Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands Calcium metabolism and the Parathyroid Glands Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands Calcium is an essential element for contraction of voluntary/smooth

More information

Forteo (teriparatide) Prior Authorization Program Summary

Forteo (teriparatide) Prior Authorization Program Summary Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis

More information

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1 Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in

More information

Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis by survey season

Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis by survey season University of Massachusetts Amherst From the SelectedWorks of Kalpana Poudel-Tandukar Summer August 19, 2009 Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis

More information

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone

More information

Effective Health Care

Effective Health Care Number 12 Effective Health Care Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis Executive Summary Background Osteoporosis is a systemic

More information

Original Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT

Original Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Original Article Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Objective: To compare Fracture Risk Assessment Tool (FRAX) calculations with and without bone

More information

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011 Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis

More information

Statistical analysis plan - The Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID

Statistical analysis plan - The Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID Statistical analysis plan - The Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID Note: This statistical analysis plan was written prior to unblinding of randomisation / treatment allocation.

More information

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis Update. Greg Summers Consultant Rheumatologist Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o

More information

REVIEW ARTICLE. Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency

REVIEW ARTICLE. Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency REVIEW ARTICLE Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency A Meta-analysis of Randomized led Trials Heike A. Bischoff-Ferrari, DrPH; Walter C. Willett, DrPH; John B. Wong,

More information

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014 Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis

More information

SCIENTIFIC DISCUSSION. London, 24 May 2007 Product name: FORSTEO Procedure No: EMEA/H/C/000425/II/0011

SCIENTIFIC DISCUSSION. London, 24 May 2007 Product name: FORSTEO Procedure No: EMEA/H/C/000425/II/0011 SCIENTIFIC DISCUSSION London, 24 May 2007 Product name: FORSTEO Procedure No: EMEA/H/C/000425/II/0011 TABLE OF CONTENTS I. INTRODUCTION... 3 II. CLINICAL ASPECTS... 4 2.1 Clinical pharmacology... 4 2.2

More information